Cardarelli Hospital
19
5
5
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
5.3%
1 terminated/withdrawn out of 19 trials
85.7%
-0.8% vs industry average
5%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease
Role: lead
During Chest Surgery, One Lung is Isolated From Ventilation to Improve Visibility, With Carbon Dioxide Introduced Between the Lung and Chest Wall (Capnothorax): the Study Seeks to Optimize Ventilation Through Esophageal Pressure Measurement, Reducing Respiratory Complications.
Role: lead
Environmental Pollutants in COPD and Lung Cancer
Role: collaborator
NBI for Early Diagnosis of OPMD/OSCC
Role: lead
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Role: collaborator
High Flow Oxygen Therapy in Patients Undergoing Bronchoscopy Under Sedation
Role: lead
Impact of High Flow Therapy on Complications Related to Airway Stenting
Role: lead
Pollutants in the Atherosclerotic Plaque and Cardiovascular Events
Role: collaborator
The Damage Control Strategy for the Treatment of Perforated Diverticulitis of the Sigmoid Colon With Diffuse Peritonitis
Role: collaborator
Genetic Bases of COVID-19 Clinical Variability
Role: collaborator
Cardioprotective Effect of SGLT2-I in Diabetic Patients With AMI (SGLT2-I AMI PROTECT Study)
Role: collaborator
Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)
Role: collaborator
Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction
Role: collaborator
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
Role: collaborator
Protoves M1® Syrup in Controlling Adverse Event During HIVEC® Instillations
Role: lead
Hepatitis C Virus Infection in Patients With Hemoglobinopathies
Role: collaborator
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
Role: lead
Early Precut in Difficult Biliary Cannulation
Role: collaborator
Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma
Role: lead
All 19 trials loaded